Evidence map›Paper›PMID 37386589›Full record

ReviewJournal of anesthesia, analgesia and critical care2022

Levosimendan in intensive care and emergency medicine: literature update and expert recommendations for optimal efficacy and safety.

M Girardis, D Bettex, M Bojan, C Demponeras, S Fruhwald, J Gál, H V Groesdonk, F Guarracino, J L Guerrero-Orriach, M Heringlake and 15 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of anesthesia, analgesia and critical care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Observational
  4. Dobutamine administration: a proposal for a standardized approach.Intensive care medicine experimental · 2025
    Article
  5. Article
  6. Article
  7. Novel inhaled pulmonary vasodilators in adult cardiac surgery: a scoping review.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2024
    Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

M GirardisAnesthesiology Unit, University Hospital of Modena, University of Modena & Reggio Emilia, Modena, Italy.
D BettexCardio-Surgical Intensive Care Unit, Institute of Anesthesiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
M BojanAnesthesiology and Intensive Care, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
C DemponerasIntensive Care Unit, Sotiria General Hospital, Athens, Greece.
S FruhwaldDepartment of Anaesthesiology and Intensive Care Medicine, Division of Anaesthesiology for Cardiovascular Surgery and Intensive Care Medicine, Medical University of Graz, Graz, Austria.
J GálDepartment of Anaesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary.
H V GroesdonkClinic for Interdisciplinary Intensive Medicine and Intermediate Care, Helios Clinic, Erfurt, Germany.
F GuarracinoDipartimento di Anestesia e Rianimazione, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
J L Guerrero-OrriachInstitute of Biomedical Research in Malaga, Department of Anesthesiology, Virgen de la Victoria University Hospital, Department of Pharmacology and Pediatrics, School of Medicine, University of Malaga, Malaga, Spain.
M HeringlakeDepartment of Anesthesiology and Intensive Care Medicine, Heart and Diabetes Center, Mecklenburg-Western Pomerania, Karlsburg Hospital, Karlsburg, Germany.
A HerpainDepartment of Intensive Care, Erasme University Hospital, Université Libre De Bruxelles, Brussels, Belgium.
L HeunksDepartment of Intensive Care, University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
J JinThe Fourth Hospital of Changsha, Changsha City, Hunan Province, People's Republic of China.
D Kindgen-MillesInterdisciplinary Surgical Intensive Care Unit, Department of Anesthesiology, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany.
P MauriatDepartment of Anaesthesia and Critical Care, University of Bordeaux, Haut-Levêque Hospital, Pessac, France.
G MichelsClinic for Acute and Emergency Medicine, St. Antonius Hospital, Eschweiler, Germany.
V PsallidaIntensive Care Unit, Agioi Anargyroi Hospital, Athens, Greece.
S RichNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
S-E RickstenDepartment of Anesthesiology and Intensive Care Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
A RudigerDepartment of Medicine, Limmattal Hospital, Limmartal, Switzerland.
M SiegemundIntensive Care Unit, Department Acute Medicine, University Hospital Basel, Basel, Switzerland.
W TollerDepartment of Anaesthesiology and Intensive Care Medicine, Division of Anaesthesiology for Cardiovascular Surgery and Intensive Care Medicine, Medical University of Graz, Graz, Austria.
S TreskatschCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt Universität zu Berlin, Department of Anesthesiology and Intensive Care Medicine, Charité Campus Benjamin Franklin, Berlin, Germany.
Ž ŽupanDepartment of Anesthesiology, Intensive Care Medicine and Pain Therapy, KBC Rijeka, Rijeka, Croatia.
P PolleselloCritical Care, Orion Pharma, P.O. Box 65, FIN-02101, Espoo, Finland. piero.pollesello@orionpharma.com.ORCID http://orcid.org/0000-0001-6994-768X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inodilator levosimendan, in clinical use for over two decades, has been the subject of extensive clinical and experimental evaluation in various clinical settings beyond its principal indication in the management of acutely decompensated chronic heart failure. Critical care and emergency medicine applications for levosimendan have included postoperative settings, septic shock, and cardiogenic shock. As the experience in these areas continues to expand, an international task force of experts from 15 countries (Austria, Belgium, China, Croatia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Spain, Sweden, Switzerland, and the USA) reviewed and appraised the latest additions to the database of levosimendan use in critical care, considering all the clinical studies, meta-analyses, and guidelines published from September 2019 to November 2021. Overall, the authors of this opinion paper give levosimendan a "should be considered" recommendation in critical care and emergency medicine settings, with different levels of evidence in postoperative settings, septic shock, weaning from mechanical ventilation, weaning from veno-arterial extracorporeal membrane oxygenation, cardiogenic shock, and Takotsubo syndrome, in all cases when an inodilator is needed to restore acute severely reduced left or right ventricular ejection fraction and overall haemodynamic balance, and also in the presence of renal dysfunction/failure.

Indexed as

Acute cardiac careEmergency medicineHaemodynamicInodilatorInotropeIntensive care unitLevosimendanRenal dysfunction

Identifiers

PMID37386589
PMCPMC8785009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.